CAR macrophages tuning the immune symphony of anti-cancer therapies.

Autor:	Paasch D; Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, 30625 Hannover, Germany., Lachmann N; Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, 30625 Hannover, Germany; RESIST, Cluster of Excellence, Hannover Medical School, 30625 Hannover, Germany; Biomedical Research in End Stage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany; Center of Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, 30625 Hannover, Germany. Electronic address: lachmann.nico@mh-hannover.de.
Jazyk:	angličtina
Zdroj:	Cell stem cell [Cell Stem Cell] 2024 Jun 06; Vol. 31 (6), pp. 791-793.
DOI:	10.1016/j.stem.2024.05.006
Abstrakt:	Chimeric antigen receptor (CAR) macrophages have broadened the landscape of anti-cancer immunotherapies to combat solid malignancies. Shah et al. introduce CARs to facilitate a CAR macrophage therapy, which aims to recruit and activate T/natural killer cells, further strengthening the overall immune response to decrease pancreatic cancer burden and metastatic spreading. Competing Interests: Declaration of interests N.L. declares a patent application (granted) on the generation of human iPS cell-derived macrophages (IP PCT/EP2018/061574). (Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu